Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
PSTV 
Plus Therapeutics Inc (PSTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: PSTV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.65% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.08M USD | Price to earnings Ratio - | 1Y Target Price 15.75 |
Price to earnings Ratio - | 1Y Target Price 15.75 | ||
Volume (30-day avg) 27417 | Beta 0.7 | 52 Weeks Range 0.93 - 2.67 | Updated Date 02/21/2025 |
52 Weeks Range 0.93 - 2.67 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.37 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -225.07% | Operating Margin (TTM) -260.92% |
Management Effectiveness
Return on Assets (TTM) -90.42% | Return on Equity (TTM) -522.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5687599 | Price to Sales(TTM) 1.24 |
Enterprise Value 5687599 | Price to Sales(TTM) 1.24 | ||
Enterprise Value to Revenue 18.19 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 5896330 | Shares Floating 5185235 |
Shares Outstanding 5896330 | Shares Floating 5185235 | ||
Percent Insiders 2.34 | Percent Institutions 11.5 |
AI Summary
Plus Therapeutics Inc.: A Comprehensive Overview
Company Profile
History and Background
Plus Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the development of innovative RNA-targeted therapies for the treatment of liver diseases. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. Plus Therapeutics has a strong scientific team with expertise in RNA biology, drug development, and clinical research.
Core Business Areas
Plus Therapeutics focuses on two main business areas:
- Development of novel RNA-targeted therapies: The company is developing a pipeline of RNA-targeted therapies, including gene editing and gene silencing technologies, for the treatment of liver diseases such as hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC).
- Collaboration with leading research institutions: Plus Therapeutics collaborates with leading research institutions and pharmaceutical companies to advance its RNA-targeted therapies.
Leadership Team and Corporate Structure
Plus Therapeutics is led by a team of experienced executives with expertise in drug development, clinical research, and business development. The company's leadership team includes:
- David W. Druey, Ph.D., President and Chief Executive Officer: Dr. Druey has over 20 years of experience in the pharmaceutical industry, including leadership roles at Genzyme Corporation and Sanofi-Aventis.
- Mark W. Erion, M.D., Ph.D., Chief Medical Officer: Dr. Erion has over 20 years of experience in clinical research and development, including leadership roles at Vertex Pharmaceuticals and GlaxoSmithKline.
- Mark B. Seltzer, Chief Financial Officer: Mr. Seltzer has over 20 years of experience in finance and accounting, including leadership roles at Ironwood Pharmaceuticals and Alexion Pharmaceuticals.
Top Products and Market Share
Top Products and Offerings
Plus Therapeutics' lead product candidate is RGLS5050, an RNAi therapeutic designed to target HBV infection in the liver. The company also has a pipeline of other RNA-targeted therapies in development for various liver diseases.
Market Share Analysis
The market for RNA-targeted therapies for liver diseases is still emerging. However, Plus Therapeutics is well-positioned to capture a significant market share given its innovative technology platform and experienced leadership team.
Competitive Landscape
Plus Therapeutics faces competition from other companies developing RNA-targeted therapies for liver diseases, such as Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, and Arrowhead Pharmaceuticals.
Total Addressable Market
The global market for RNA-targeted therapies for liver diseases is estimated to be worth over $10 billion by 2025. Plus Therapeutics has the potential to capture a significant share of this market with its innovative products and experienced leadership team.
Financial Performance
Recent Financial Statements
Plus Therapeutics is a clinical-stage company and does not currently generate revenue. The company's financial performance is primarily driven by research and development expenses.
Financial Health
Plus Therapeutics has a strong cash position and is well-funded to advance its clinical development programs.
Dividends and Shareholder Returns
Plus Therapeutics does not currently pay dividends.
Growth Trajectory
Plus Therapeutics has a strong growth trajectory driven by its innovative product pipeline and experienced leadership team. The company is expected to initiate Phase 2 clinical trials for its lead product candidate, RGLS5050, in 2023.
Market Dynamics
The RNA-targeted therapy market for liver diseases is rapidly growing, driven by the increasing prevalence of liver diseases and the potential for these therapies to offer a cure for these diseases.
Competitors
- Alnylam Pharmaceuticals (
ALNY) - Dicerna Pharmaceuticals (
DRNA) - Arrowhead Pharmaceuticals (
ARWR)
Potential Challenges and Opportunities
Key Challenges
- Competition from other companies developing RNA-targeted therapies for liver diseases
- Regulatory hurdles in the development and approval of new therapies
- The uncertainty of clinical trial outcomes
Potential Opportunities
- Growing market for RNA-targeted therapies for liver diseases
- Strategic partnerships with leading pharmaceutical companies
- Expanding product pipeline into new therapeutic areas
Recent Acquisitions
Plus Therapeutics has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating
Based on an AI-based analysis of Plus Therapeutics' financials, market position, and future prospects, the company receives a rating of 7 out of 10.
This rating is supported by the company's strong cash position, experienced leadership team, and innovative product pipeline. However, the company also faces challenges such as competition from other companies developing RNA-targeted therapies for liver diseases and the uncertainty of clinical trial outcomes.
Sources and Disclaimers
This overview is based on information from Plus Therapeutics' website and other publicly available sources. The information provided is for general knowledge and informational purposes only, and does not constitute professional financial advice. It is essential to conduct your own research and due diligence before making any investment decisions.
About Plus Therapeutics Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2000-11-16 | President, CEO & Director Dr. Marc H. Hedrick M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://plustherapeutics.com |
Full time employees 20 | Website https://plustherapeutics.com | ||
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.